

Press Release

ProStrakan Group plc

Sancuso® - PDUFA Action Date Market Update

Galashiels, Scotland, 18 July, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has been notified that the US Food and Drug Administration (FDA) continues to experience resource issues and, as a result, the FDA is unlikely to meet the latest action date for Sancuso®, which is today, Friday 18 July. Sancuso is ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Although the FDA has missed its previously stated action dates, the Company understands that this has been due to a lack of resources at the FDA rather than review issues. ProStrakan remains confident of gaining approval during this current procedure and continues to plan for the US launch of Sancuso in H2 2008. The Company will provide the next update when there is more certainty around an actual FDA action date.

Ends

For more information on this announcement, please contact:

ProStrakan Corporate +44 (0)1896 664000
Dr Wilson Totten, Chief Executive
Callum Spreng, Corporate Comms

Financial Dynamics +44 (0)20 7831 3113
David Yates / Ben Brewerton

Trout Group (for US investor enquiries)
Gitanjali Jain (646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is situated in Galashiels in Scotland. The company's development capability is centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's existing portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries.
www.prostrakan.com